JP6353654B2 - 抗血管新生剤及びこのような薬剤の使用方法 - Google Patents

抗血管新生剤及びこのような薬剤の使用方法 Download PDF

Info

Publication number
JP6353654B2
JP6353654B2 JP2013519804A JP2013519804A JP6353654B2 JP 6353654 B2 JP6353654 B2 JP 6353654B2 JP 2013519804 A JP2013519804 A JP 2013519804A JP 2013519804 A JP2013519804 A JP 2013519804A JP 6353654 B2 JP6353654 B2 JP 6353654B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
angiogenic
pharmaceutical composition
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013519804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534538A (ja
Inventor
リュー，ジー‐レン
ヤン，ジェニー・ジェイ
ルー，イン
Original Assignee
ジョージア・ステイト・ユニヴァーシティ・リサーチ・ファウンデイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョージア・ステイト・ユニヴァーシティ・リサーチ・ファウンデイション filed Critical ジョージア・ステイト・ユニヴァーシティ・リサーチ・ファウンデイション
Publication of JP2013534538A publication Critical patent/JP2013534538A/ja
Application granted granted Critical
Publication of JP6353654B2 publication Critical patent/JP6353654B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2013519804A 2010-07-13 2011-07-13 抗血管新生剤及びこのような薬剤の使用方法 Active JP6353654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36393310P 2010-07-13 2010-07-13
US61/363,933 2010-07-13
PCT/US2011/043907 WO2012009471A1 (en) 2010-07-13 2011-07-13 Anti-angiogenic agent and method of using such agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016078990A Division JP2016175913A (ja) 2010-07-13 2016-04-11 抗血管新生剤及びこのような薬剤の使用方法

Publications (2)

Publication Number Publication Date
JP2013534538A JP2013534538A (ja) 2013-09-05
JP6353654B2 true JP6353654B2 (ja) 2018-07-04

Family

ID=44629339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519804A Active JP6353654B2 (ja) 2010-07-13 2011-07-13 抗血管新生剤及びこのような薬剤の使用方法
JP2016078990A Pending JP2016175913A (ja) 2010-07-13 2016-04-11 抗血管新生剤及びこのような薬剤の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016078990A Pending JP2016175913A (ja) 2010-07-13 2016-04-11 抗血管新生剤及びこのような薬剤の使用方法

Country Status (12)

Country Link
US (2) US9175063B2 (enExample)
EP (2) EP2593127B1 (enExample)
JP (2) JP6353654B2 (enExample)
CN (1) CN103002904B (enExample)
AU (5) AU2011279155B2 (enExample)
CA (1) CA2804753C (enExample)
DK (1) DK2593127T3 (enExample)
ES (2) ES2674409T3 (enExample)
HU (1) HUE040205T2 (enExample)
PL (1) PL2593127T3 (enExample)
PT (2) PT3381462T (enExample)
WO (1) WO2012009471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3381462T (pt) * 2010-07-13 2022-07-22 Georgia State Univ Research Foundation Agente antiangiogénico e método de utilização de tal agente
US20180044403A1 (en) * 2015-03-06 2018-02-15 Georgia State University Research Foundation, Inc. Integrin-targeting protein and methods of use thereof
CN110452295B (zh) * 2015-11-10 2022-10-11 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物
CN108148117A (zh) * 2017-12-26 2018-06-12 张艳雪 一种抗菌肽的蛋白质结构特性及其研究方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
CA2555144A1 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
US9339559B2 (en) * 2005-09-09 2016-05-17 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
WO2009146099A2 (en) * 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
JP5792066B2 (ja) * 2008-09-08 2015-10-07 ホフマン／バーレット， リミテッド ライアビリティ カンパニー ポルフィラジン並びに光学的及びデュアル光学的／ｍｒコントラスト並びに治療薬
PT3381462T (pt) * 2010-07-13 2022-07-22 Georgia State Univ Research Foundation Agente antiangiogénico e método de utilização de tal agente

Also Published As

Publication number Publication date
AU2019202174B2 (en) 2020-11-26
WO2012009471A1 (en) 2012-01-19
JP2013534538A (ja) 2013-09-05
EP2593127B1 (en) 2018-05-30
ES2923430T3 (es) 2022-09-27
PL2593127T3 (pl) 2018-11-30
HUE040205T2 (hu) 2019-02-28
CA2804753A1 (en) 2012-01-19
AU2017201133A1 (en) 2017-03-09
EP2593127A1 (en) 2013-05-22
CA2804753C (en) 2021-05-25
DK2593127T3 (en) 2018-07-02
AU2011279155B2 (en) 2017-03-09
AU2019202174A1 (en) 2019-04-18
US20160090408A1 (en) 2016-03-31
AU2021201207A1 (en) 2021-03-11
AU2023202513A1 (en) 2023-05-11
JP2016175913A (ja) 2016-10-06
US20130281357A1 (en) 2013-10-24
EP3381462A1 (en) 2018-10-03
CN103002904B (zh) 2017-01-18
US9175063B2 (en) 2015-11-03
PT3381462T (pt) 2022-07-22
AU2011279155A1 (en) 2013-01-24
ES2674409T3 (es) 2018-06-29
CN103002904A (zh) 2013-03-27
EP3381462B1 (en) 2022-06-08
PT2593127T (pt) 2018-07-06
US11578114B2 (en) 2023-02-14

Similar Documents

Publication Publication Date Title
Ylä-Herttuala et al. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine
AU2023202513A1 (en) Anti-angiogenic agent and method of using such agent
EP3830114A1 (en) Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor
US20210008173A1 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
JP2025078632A (ja) インテグリン標的タンパク質およびその使用方法
US12410230B2 (en) Anti-angiogenic agent and methods of using such agent
US20240390465A1 (en) Endostatin Peptides for the Treatment of Tumors, Fibrosis and Acute Lung Injury
WO2024173546A2 (en) Anti-angiogenic agent and methods of using such agent
EP4665378A2 (en) Anti-angiogenic agent and methods of using such agent
RU2806524C2 (ru) Белок, нацеленный на интегрин, и способы его применения
EP4171649A2 (en) Use of caveolin-1 scaffolding domain peptides for treating disease and disorders
JPWO2019146621A1 (ja) ペリオスチンの発現量増加またはスプライシングバリアントの変化を伴う疾患の治療用医薬組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160601

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180611

R150 Certificate of patent or registration of utility model

Ref document number: 6353654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250